Advances in tau-based drug discovery

Bibliography

• Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener 2009;4:13
   PubMed Web of Science ®Google Scholar
• Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007;8:663-72
   PubMed Web of Science ®Google Scholar
• Available from: www.alz.co.uk/dementia [Last accessed 4 April 2011]
   Google Scholar
• Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010;68:270-81
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Weisgraber KH, Huang DY, Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:8098-102
   PubMed Web of Science ®Google Scholar
• Harold D, Abraham R, Hollingworth P, Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088-93
   PubMed Web of Science ®Google Scholar
• Lambert JC, Heath S, Even G, Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41:1094-9
   PubMed Web of Science ®Google Scholar
• Hutton M, Lendon CL, Rizzu P, Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-5
   PubMed Web of Science ®Google Scholar
• Wolfe MS. Tau mutations in neurodegenerative diseases. J Biol Chem 2009;284:6021-5
   PubMed Web of Science ®Google Scholar
• Roberson ED, Scearce-Levie K, Palop JJ, Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316:750-4
   PubMed Web of Science ®Google Scholar
• Rapoport M, Dawson HN, Binder LI, Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 2002;99:6364-9
   PubMed Web of Science ®Google Scholar
• Ittner LM, Gotz J. Amyloid-beta and tau - a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011;12:65-72
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Lowe VJ, Weigand SD, Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-65
   PubMed Web of Science ®Google Scholar
• Hanger DP, Seereeram A, Noble W. Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease. Expert Rev Neurother 2009;9:1647-66
   PubMed Web of Science ®Google Scholar
• Takanashi M, Mori H, Arima K, Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. Brain Res Mol Brain Res 2002;104:210-19
   PubMedGoogle Scholar
• Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 2008;5:443-57
   PubMed Web of Science ®Google Scholar
• Takashima A, Murayama M, Murayama O, Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci U S A 2002;95:9637-9641
   Google Scholar
• Sontag E, Nunbhakdi-Craig V, Lee G, Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem 1999;274:25490-8
   PubMed Web of Science ®Google Scholar
• Kampers T, Friedhoff P, Biernat J, RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett 1996;399:344-9
   PubMed Web of Science ®Google Scholar
• Li W, Wang XS, Qu MH, Human protein tau represses DNA replication in vitro. Biochim Biophys Acta 2005;1726:280-6
   PubMed Web of Science ®Google Scholar
• Brandt R, Leger J, Lee G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol 1995;131:1327-40
   PubMed Web of Science ®Google Scholar
• Pooler AM, Usardi A, Evans CJ, Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging 2011; published online 7 March 2011, doi:10.1016/j.neurobiolaging.2011.01.005
   PubMed Web of Science ®Google Scholar
• Reynolds CH, Garwood CJ, Wray S, Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem 2008;283:18177-86
   PubMed Web of Science ®Google Scholar
• Ittner LM, Ke YD, Delerue F, Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010;142:387-97
   PubMed Web of Science ®Google Scholar
• Hanger DP, Byers HL, Wray S, Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 2007;282:23645-54
   PubMed Web of Science ®Google Scholar
• Lebouvier T, Scales TM, Williamson R, The microtubule-associated protein tau is also phosphorylated on tyrosine. J Alzheimers Dis 2009;18:1-9
   PubMed Web of Science ®Google Scholar
• Schneider A, Biernat J, von Bergen M, Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999;38:3549-58
   PubMed Web of Science ®Google Scholar
• Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int 2011, published online 6 Jan 2011, doi:10.1016/j.neuint.2010.12.023
   Google Scholar
• Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 2009;8:783-93
   PubMed Web of Science ®Google Scholar
• Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 1996;2:783-7
   PubMed Web of Science ®Google Scholar
• Mandelkow EM, Stamer K, Vogel R, Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003;24:1079-85
   PubMed Web of Science ®Google Scholar
• Cuchillo-Ibanez I, Seereeram A, Byers HL, Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J 2008;22:3186-95
   PubMed Web of Science ®Google Scholar
• Berger Z, Roder H, Hanna A, Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007;27:3650-62
   PubMed Web of Science ®Google Scholar
• Ramsden M, Kotilinek L, Forster C, Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005;25:10637-47
   PubMed Web of Science ®Google Scholar
• Santacruz K, Lewis J, Spires T, Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005;309:476-81
   PubMed Web of Science ®Google Scholar
• Andorfer C, Acker CM, Kress Y, Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005;25:5446-54
   PubMed Web of Science ®Google Scholar
• Hoover BR, Reed MN, Su J, Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010;68:1067-81
   PubMed Web of Science ®Google Scholar
• Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996;93:8455-9
   PubMed Web of Science ®Google Scholar
• Leclerc S, Garnier M, Hoessel R, Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001;276:251-60
   PubMed Web of Science ®Google Scholar
• Leost M, Schultz C, Link A, Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem 2000;267:5983-94
   PubMedGoogle Scholar
• Martinez A, Alonso M, Castro A, First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002;45:1292-9
   PubMed Web of Science ®Google Scholar
• Coghlan MP, Culbert AA, Cross DA, Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793-803
   PubMed Web of Science ®Google Scholar
• Bhat R, Xue Y, Berg S, Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937-45
   PubMed Web of Science ®Google Scholar
• Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001;280:720-5
   PubMed Web of Science ®Google Scholar
• Engel T, Goni-Oliver P, Lucas JJ, Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 2006;99:1445-55
   PubMed Web of Science ®Google Scholar
• Leroy K, Ando K, Heraud C, Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis 2010;19:705-19
   PubMed Web of Science ®Google Scholar
• Noble W, Planel E, Zehr C, Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005;102:6990-5
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003;423:435-9
   PubMed Web of Science ®Google Scholar
• Hampel H, Ewers M, Burger K, Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009;70:922-31
   PubMed Web of Science ®Google Scholar
• Selenica ML, Jensen HS, Larsen AK, Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol 2007;152:959-79
   PubMed Web of Science ®Google Scholar
• Martin L, Magnaudeix A, Esclaire F, Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Brain Res 2009;1252:66-75
   PubMed Web of Science ®Google Scholar
• Bhat R, Berg S, Burrows J, Lindquist J. GSK-3 inhibitors for the treatment of Alzheimer's disease. In topics in medicinal chemistry: alzheimer's disease. Springer; 2007
   Google Scholar
• Yeh PA, Chang CJ, Tu PH, Phosphorylation alters tau distribution and elongates life span in Drosophila. J Alzheimers Dis 2010;21:543-56
   PubMed Web of Science ®Google Scholar
• Martinez A, Perez DI. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 2008;15:181-91
   PubMed Web of Science ®Google Scholar
• 5Duka T, Duka V, Joyce JN, Sidhu A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J 2009;23:2820-30
   PubMed Web of Science ®Google Scholar
• Sereno L, Coma M, Rodriguez M, A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009;35:359-67
   PubMed Web of Science ®Google Scholar
• Hu S, Begum AN, Jones MR, GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 2009;33:193-206
   PubMed Web of Science ®Google Scholar
• Hernandez F, Perez M, Lucas JJ, Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J Biol Chem 2004;279:3801-6
   PubMed Web of Science ®Google Scholar
• Available from: http://www.astrazeneca.com/article/511390.aspx [Last accessed 26 February 2011]
   Google Scholar
• Le Corre S, Klafki HW, Plesnila N, An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci USA 2006;103:9673-8
   PubMed Web of Science ®Google Scholar
• Engmann O, Giese KP. Crosstalk between Cdk5 and GSK3beta: implications for Alzheimer's disease. Front Mol Neurosci 2009;2:2
   PubMedGoogle Scholar
• Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 1993;61:921-7
   PubMed Web of Science ®Google Scholar
• Planel E, Yasutake K, Fujita SC, Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem 2001;276:34298-306
   PubMed Web of Science ®Google Scholar
• Li L, Sengupta A, Haque N, Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 2004;566:261-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.signumbiosciences.com/pipeline.html [Last accessed 26 February 2011]
   Google Scholar
• Congdon EE, Duff KE. Is tau aggregation toxic or protective? J Alzheimers Dis 2008;14:453-7
   PubMed Web of Science ®Google Scholar
• Crowe A, Huang W, Ballatore C, Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 2009;48:7732-45
   PubMed Web of Science ®Google Scholar
• Crowe A, Ballatore C, Hyde E, High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun 2007;358:1-6
   PubMed Web of Science ®Google Scholar
• Pickhardt M, von Bergen M, Gazova Z, Screening for inhibitors of tau polymerization. Curr Alzheimer Res 2005;2:219-26
   PubMedGoogle Scholar
• Taniguchi S, Suzuki N, Masuda M, Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 2005;280:7614-23
   PubMed Web of Science ®Google Scholar
• Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging 2009;13:367-9
   PubMed Web of Science ®Google Scholar
• O'Leary JC III, Li Q, Marinec P, Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener 2010;5:45
   PubMed Web of Science ®Google Scholar
• Chang E, Congdon EE, Honson NS, Structure-activity relationship of cyanine tau aggregation inhibitors. J Med Chem 2009;52:3539-47
   PubMed Web of Science ®Google Scholar
• Congdon EE, Figueroa YH, Wang L, Inhibition of tau polymerization with a cyanine dye in two distinct model systems. J Biol Chem 2009;284:20830-9
   PubMed Web of Science ®Google Scholar
• Chirita C, Necula M, Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 2004;43:2879-87
   PubMed Web of Science ®Google Scholar
• Ballatore C, Brunden KR, Piscitelli F, Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation. J Med Chem 2010;53:3739-47
   PubMed Web of Science ®Google Scholar
• Pickhardt M, Gazova Z, von Bergen M, Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 2005;280:3628-35
   PubMed Web of Science ®Google Scholar
• Khlistunova I, Biernat J, Wang Y, Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006;281:1205-14
   PubMed Web of Science ®Google Scholar
• Khlistunova I, Pickhardt M, Biernat J, Inhibition of tau aggregation in cell models of tauopathy. Curr Alzheimer Res 2007;4:544-6
   PubMed Web of Science ®Google Scholar
• Hotta N, Akanuma Y, Kawamori R, Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006;29:1538-44
   PubMed Web of Science ®Google Scholar
• Bulic B, Pickhardt M, Schmidt B, Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl 2009;48:1740-52
   PubMed Web of Science ®Google Scholar
• Salminen A, Ojala J, Kaarniranta K, Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease. Prog Neurobiol 2010; published online 5 Nov 2010, doi:10.1016/j.pneurobio.2010.10.006
   PubMed Web of Science ®Google Scholar
• Dickey CA, Dunmore J, Lu B, HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 2006;20:753-5
   PubMed Web of Science ®Google Scholar
• Dickey CA, Kamal A, Lundgren K, The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007;117:648-58
   PubMed Web of Science ®Google Scholar
• Luo W, Dou F, Rodina A, Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci USA 2007;104:9511-16
   PubMed Web of Science ®Google Scholar
• Berger Z, Ravikumar B, Menzies FM, Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 2006;15:433-42
   PubMed Web of Science ®Google Scholar
• Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007;27:9115-29
   PubMed Web of Science ®Google Scholar
• Boimel M, Grigoriadis N, Lourbopoulos A, Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010;224:472-85
   PubMed Web of Science ®Google Scholar
• Zhang B, Maiti A, Shively S, Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 2005;102:227-31
   PubMed Web of Science ®Google Scholar
• Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24:1633-42
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Gray AJ, Hirata-Fukae C, Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007;31:165-70
   PubMed Web of Science ®Google Scholar
• Shiryaev N, Jouroukhin Y, Giladi E, NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009;34:381-8
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Jouroukhin Y, Gray AJ, A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008;325:146-53
   PubMed Web of Science ®Google Scholar
• Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007;6:341-2
   PubMed Web of Science ®Google Scholar
• Brunden KR, Zhang B, Carroll J, Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 2010;30:13861-6
   PubMed Web of Science ®Google Scholar
• Kalbfuss B, Mabon SA, Misteli T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem 2001;276:42986-93
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martin T, Garcia-Blanco MA, Mansfield SG, Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. Proc Natl Acad Sci USA 2005;102:15659-64
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54
   PubMed Web of Science ®Google Scholar
• Dodel R, Neff F, Noelker C, Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 2010;70:513-28
   PubMed Web of Science ®Google Scholar
• Oddo S, Vasilevko V, Caccamo A, Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 2006;281:39413-23
   PubMed Web of Science ®Google Scholar
• Brunden KR, Ballatore C, Crowe A, Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 2010;223:304-10
   PubMed Web of Science ®Google Scholar
• Hu WT, Chen-Plotkin A, Arnold SE, Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol 2010;120:385-99
   PubMed Web of Science ®Google Scholar
• Hampel H, Frank R, Broich K, Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560-74
   PubMed Web of Science ®Google Scholar
• Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med 2010;4:51-63
   PubMed Web of Science ®Google Scholar
• de Leon MJ, DeSanti S, Zinkowski R, Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006;27:394-401
   PubMed Web of Science ®Google Scholar
• Small GW, Kepe V, Ercoli LM, PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355:2652-63
   PubMed Web of Science ®Google Scholar
• Miyoshi M, Shinotoh H, Wszolek ZK, In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. Parkinsonism Relat Disord 2010;16:404-8
   PubMed Web of Science ®Google Scholar
• Rojo LE, Alzate-Morales J, Saavedra IN, Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis 2010;19:573-89
   PubMed Web of Science ®Google Scholar
• Available from: http://www.alz.org/research/diagnostic_criteria/preclinical_recommendations.pdf [Last accessed 4 April 2011]
   Google Scholar
• Cummings JL. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol Aging 2010;31:1481-92
   PubMed Web of Science ®Google Scholar
• van der Zee J, Sleegers K, Van Brockhoven C. Invited article: the Alzheimer disease-frontotemporal lobar degeneration spectrum. Neurology 2008;71:1191-7
   PubMed Web of Science ®Google Scholar
• Vellas B, Aisen PS. Early Alzheimer's trials: new developments. J Nutr Health Aging 2010;14:293
   PubMed Web of Science ®Google Scholar
• Iqbal K, Flory M, Khatoon S, Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005;58:748-57
   PubMed Web of Science ®Google Scholar
• Available from: http://www.researchals.org/page/4746/6097/ [Last accessed 26 February 2011]
   Google Scholar